YIDA CHINA (03639) contract sales amount in the first two months was approximately 0.18 billion yuan, a year-on-year decrease of 84.48%.
Yida China (03639) announced that in February 2026, the Group's contract sales amounted to approximately RMB 0.07 billion, a decrease of 87.04% year-on-year; and equity contract sales amounted to approximately RMB 0.07 billion, a decrease of 83.33% year-on-year. During the same period, the Group's sales area was 489 square meters and equity sales area was 489 square meters, with an average selling price of about RMB 13,784 per square meter and an equity selling price of about RMB 13,784 per square meter.
YIDA CHINA (03639) announced that in February 2026, the Group's contract sales amounted to approximately RMB 0.07 billion, a decrease of 87.04% year-on-year; and equity contract sales amounted to approximately RMB 0.07 billion, a decrease of 83.33% year-on-year. During the same period, the Group's sales area was 489 square meters and equity sales area was 489 square meters, with an average selling price of approximately RMB 13,784 per square meter and an equity selling price of approximately RMB 13,784 per square meter.
In January and February, the Group's contract sales amounted to approximately RMB 0.18 billion, a decrease of 84.48% year-on-year; and equity contract sales amounted to approximately RMB 0.18 billion, a decrease of 82.35% year-on-year. During the same period, the Group's sales area was 1,404 square meters and equity sales area was 1,404 square meters, with an average selling price of approximately RMB 12,688 per square meter and an equity selling price of approximately RMB 12,688 per square meter.
Related Articles

In the first two months of the year, the total sales of property contracts in Central China (00832) decreased by 37.7% year-on-year to 9.8 billion yuan.

Jiangsu Hengrui Pharmaceuticals (01276): The application for marketing approval of Sucranolide insulin analog injection has been accepted by the National Medical Products Administration.

CICC (03908) plans to redeem "21 CICC Y2"
In the first two months of the year, the total sales of property contracts in Central China (00832) decreased by 37.7% year-on-year to 9.8 billion yuan.

Jiangsu Hengrui Pharmaceuticals (01276): The application for marketing approval of Sucranolide insulin analog injection has been accepted by the National Medical Products Administration.

CICC (03908) plans to redeem "21 CICC Y2"

RECOMMEND

“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026

Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026

U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026


